Simplify Asset Management Inc. Purchases 25,456 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Simplify Asset Management Inc. boosted its holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 20.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 147,641 shares of the company's stock after purchasing an additional 25,456 shares during the period. Simplify Asset Management Inc. owned about 0.17% of Syndax Pharmaceuticals worth $1,952,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. KLP Kapitalforvaltning AS purchased a new position in shares of Syndax Pharmaceuticals in the 4th quarter worth about $219,000. Teacher Retirement System of Texas raised its position in Syndax Pharmaceuticals by 18.7% in the fourth quarter. Teacher Retirement System of Texas now owns 22,769 shares of the company's stock worth $301,000 after acquiring an additional 3,585 shares during the period. AlphaQuest LLC boosted its stake in Syndax Pharmaceuticals by 32.3% in the fourth quarter. AlphaQuest LLC now owns 23,623 shares of the company's stock valued at $312,000 after acquiring an additional 5,765 shares during the last quarter. E Fund Management Co. Ltd. grew its position in shares of Syndax Pharmaceuticals by 14.4% during the 4th quarter. E Fund Management Co. Ltd. now owns 12,603 shares of the company's stock valued at $167,000 after acquiring an additional 1,583 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of Syndax Pharmaceuticals by 1.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 704,823 shares of the company's stock worth $9,318,000 after purchasing an additional 8,876 shares during the last quarter.

Syndax Pharmaceuticals Stock Up 3.3 %

SNDX traded up $0.43 during trading on Thursday, reaching $13.56. 866,315 shares of the company were exchanged, compared to its average volume of 1,451,654. Syndax Pharmaceuticals, Inc. has a 12-month low of $12.06 and a 12-month high of $25.07. The company's 50-day moving average is $14.29 and its two-hundred day moving average is $15.94. The company has a market cap of $1.17 billion, a price-to-earnings ratio of -3.74 and a beta of 0.92.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last announced its quarterly earnings results on Monday, March 3rd. The company reported ($1.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.79). The firm had revenue of $7.68 million for the quarter, compared to analysts' expectations of $86.32 million. Equities analysts forecast that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current year.

Analyst Upgrades and Downgrades

SNDX has been the topic of several research analyst reports. JPMorgan Chase & Co. upped their price objective on Syndax Pharmaceuticals from $39.00 to $41.00 and gave the company an "overweight" rating in a research note on Thursday, March 20th. HC Wainwright reaffirmed a "buy" rating and set a $51.00 price target on shares of Syndax Pharmaceuticals in a research report on Tuesday, March 4th. Citigroup cut their price target on Syndax Pharmaceuticals from $45.00 to $42.00 and set a "buy" rating for the company in a research note on Tuesday, March 4th. Finally, Scotiabank lowered their price objective on Syndax Pharmaceuticals from $18.00 to $16.00 and set a "sector perform" rating on the stock in a research note on Wednesday, January 8th. One analyst has rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $36.20.

Insider Buying and Selling at Syndax Pharmaceuticals

In related news, insider Neil Gallagher sold 4,618 shares of the firm's stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $15.50, for a total value of $71,579.00. Following the sale, the insider now directly owns 85,095 shares of the company's stock, valued at $1,318,972.50. This trade represents a 5.15 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Michael A. Metzger sold 13,288 shares of Syndax Pharmaceuticals stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $15.50, for a total transaction of $205,964.00. Following the sale, the chief executive officer now owns 300,121 shares of the company's stock, valued at approximately $4,651,875.50. The trade was a 4.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 21,683 shares of company stock valued at $336,087 in the last three months. Company insiders own 4.10% of the company's stock.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).